← Back to Clinical Trials
Recruiting NCT05982262

NCT05982262 Naturopathic-pharmacological Consultation in Hematology

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05982262
Status Recruiting
Phase
Sponsor Bnai Zion Medical Center
Condition Hematologic Diseases
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-06-15
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Naturopathic-pharmacological consultation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-06-15 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. The main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients. Participants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. Some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.

Eligibility Criteria

Inclusion Criteria: 1. Followed up for a hematological condition 2. Ability to fill simple questionnaires in Hebrew, Russian or Arabic 3. Indication for consultation: 1. Patient's request to expand knowledge about the use of DHS 2. Patient using DHS 3. Patient's desire to start using DHS 4. Patient that is interested in hearing about the use of DHS for his/her health condition 5. Medical or nursing team's recommendation to take DHS for medical treatment or to improve compliance with conventional treatment. Exclusion Criteria: None

Contact & Investigator

Central Contact

Dana Weizer

✉ dana.weizer@b-zion.org.il

📞 972543295952

Principal Investigator

Ilana Levy Yurkovski, MD

PRINCIPAL INVESTIGATOR

Bnai Zion Medical Center

Frequently Asked Questions

Who can join the NCT05982262 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05982262 currently recruiting?

Yes, NCT05982262 is actively recruiting participants. Contact the research team at dana.weizer@b-zion.org.il for enrollment information.

Where is the NCT05982262 trial being conducted?

This trial is being conducted at Haifa, Israel.

Who is sponsoring the NCT05982262 clinical trial?

NCT05982262 is sponsored by Bnai Zion Medical Center. The principal investigator is Ilana Levy Yurkovski, MD at Bnai Zion Medical Center. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology